Eli Lilly plans $800 million two-part notes in five-, 30-year tranches

By Aleesia Forni

Virginia Beach, Feb. 20 - Eli Lilly & Co. intends to sell $800 million notes in two parts, according to a syndicate source and a 424B2 filed with the Securities and Exchange Commission on Thursday.

The sale will include tranches due 2019 and 2044.

BofA Merrill Lynch, Barclays, Citigroup Global Markets Inc. and Morgan Stanley & Co. LLC are the joint bookrunners.

The company expects to use proceeds from the sale of the notes for general corporate purposes, including the repayment of its $1 billion 4.2% notes due March 6, 2014.

The pharmaceutical company is based in Indianapolis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.